

REMARKS

The Examiner's courtesy and cooperation in several telephone interviews in connection with this case are appreciately acknowledged.

As a result of the foregoing amendment, claims 1, 13 and 15 have been modified to delete the phrase "or derivatives thereof". Claim 11 has been amended to be dependant on claim 7 and thus obviate the formal rejection thereof. In addition, the expression "the recitation of a lower alcohol group" has been deleted from Claim 1 and thus all of the remaining claims which are directly or indirectly dependent from Claim 1.


This clearly avoids the rejection over the Brush reference. In addition, the rejection of the claims as being anticipated by the Frame, et al. article in Tetrahedron has also been obviated. Frame only discloses 5-amino-4-sulfonamidoimidazole nucleosides as potential inhibitors of purine nucleotide biosynthesis. The reference is devoid of any disclosure of fluorescent nucleotides as required by the present claims.

Accordingly, this rejection is no longer tenable and should be withdrawn.

In view the foregoing amendment, it is submitted that this application is in condition for Allowance and favorable reconsideration is earnestly solicited.

Respectfully submitted,

Dated: March 8, 2006

By 
Jules E. Goldberg
Reg. No. 24,408
REED SMITH LLP
599 Lexington Avenue
29th Floor
New York, NY 10022-7650
(212) 521-5400

Attorney for Applicant